Clinical perspectives on human genetic screening to prevent nevirapine toxicity
2012
Nevirapineis one of the most extensively prescribed antiretroviral drugs worldwide. However, a concern is increased risk for severe toxicity when antiretroviral-naive individuals with higher CD4 T-cell counts initiate
nevirapine-containing regimens. Several genetic variants are associated with
nevirapinetoxicities. The authors used data from a previous study to anticipate potential consequences of
genetic screeningto prevent
nevirapineadverse events. That study enrolled cohorts of African, Asian and European descent in 11 countries, including 276 patients who had experienced severe cutaneous and/or hepatic adverse events with
nevirapine-containing regimens and 587 matched
nevirapine-tolerant controls. Associations were identified with HLA-Cw*04,
HLA-B*35, HLA-DRB*01 and
CYP2B6516G>T (rs3745274); however, positive predictive values for these genetic markers were low, and most
nevirapine-associated adverse events occurred in patients without these markers. Unless better genetic predictors are identified,
nevirapinetoxicity is best avoided by continuing to follow current prescribing guidelines that are based largely on CD4 T-cell criteria.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
26
References
3
Citations
NaN
KQI